by Plus Therapeutics | Feb 28, 2026 | LM
Today, Plus Therapeutics joins the global community in recognizing Rare Disease Day, an annual moment dedicated to raising awareness and advancing efforts for the more than 300 million people worldwide living with a rare disease. Rare Disease Day serves as a powerful...
by Plus Therapeutics | Feb 27, 2026 | Uncategorized
Radiation therapy has been a cornerstone of cancer treatment for more than a century. Its ability to damage cancer cells and control tumor growth has made it one of the most widely used and effective therapeutic modalities in oncology. Yet despite its long history and...
by Plus Therapeutics | Feb 25, 2026 | GBM
Plus Therapeutics announced that the American Medical Association (AMA) CPT® Editorial Panel has approved a new Category III CPT code to track the utilization of convection‑enhanced delivery (CED) when used in the administration of REYOBIQ™ for patients with recurrent...
by Plus Therapeutics | Feb 19, 2026 | Uncategorized
As radioligand therapies (RLTs) and theranostics continue to gain momentum across biopharma, the industry is entering a new era—one marked by tremendous opportunity, along with unique regulatory, manufacturing, and reimbursement challenges. In a recent article for...
by Plus Therapeutics | Feb 9, 2026 | Uncategorized
Pharma’s Almanac recently asked a group of biopharma leaders an important question: What emerging technologies or scientific breakthroughs will most reshape biopharma over the next decade? Among those featured was Marc Hedrick, MD, President and CEO of Plus...
Recent Comments